Amalgamated Financial’s Emergent Biosolutions EBS Stock Holding History

Amalgamated Financial’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$887K	Buy	+21,600	New	+$953K	0.01%	1232

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Amalgamated Financial's EBS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Emergent Biosolutions (EBS) in Q1 2022: 21,600 shares worth $887K. The stake represents 0.01% of the portfolio and ranks #1232 among its holdings.

255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

Amalgamated Financial held 21,600 shares of Emergent Biosolutions worth $887K as of Q1 2022.
Emergent Biosolutions was a new Amalgamated Financial position in Q1 2022.
Emergent Biosolutions made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1232 holding.
255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.